Raju Mohan - 04 Mar 2026 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
04 Mar 2026, 16:17:25 UTC
Prior SEC filing
19 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Austin Rutherford, as Attorney-in-Fact

Key filing fact

Raju Mohan filed Form 4 for Ventyx Biosciences, Inc. (VTYX) on 04 Mar 2026.

Key facts

  • This page summarizes Raju Mohan's Form 4 filing for Ventyx Biosciences, Inc. (VTYX).
  • 10 reported transactions and 9 derivative rows are listed below.
  • Accepted by SEC: 04 Mar 2026, 16:17.

Change

  • Previous filing in this sequence was filed on 19 Dec 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001878125 Primary reporting owner

Mohan Raju

Relationship
CEO AND PRESIDENT, Director
Address
C/O VENTYX BIOSCIENCES, INC., 12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Signature
/s/ Austin Rutherford, as Attorney-in-Fact
Signature date
04 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VTYX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-2,372,863
Change %
-100%
Price
Shares after
0
Date
04 Mar 2026
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VTYX transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares
-23,688
Change %
-100%
Price
Shares after
0
Date
04 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
23,688
Exercise price
Footnotes
F1, F3
VTYX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-700,000
Change %
-100%
Price
Shares after
0
Date
04 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
700,000
Exercise price
$2.14
Footnotes
F1, F4
VTYX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-155,000
Change %
-100%
Price
Shares after
0
Date
04 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
155,000
Exercise price
$2.49
Footnotes
F1, F4
VTYX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-473,750
Change %
-100%
Price
Shares after
0
Date
04 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
473,750
Exercise price
$2.14
Footnotes
F1, F4
VTYX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-370,000
Change %
-100%
Price
Shares after
0
Date
04 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
370,000
Exercise price
$12.21
Footnotes
F1, F4
VTYX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-335,286
Change %
-100%
Price
Shares after
0
Date
04 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
335,286
Exercise price
$8.04
Footnotes
F1, F4
VTYX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-7,972
Change %
-100%
Price
Shares after
0
Date
04 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,972
Exercise price
$3.54
Footnotes
F1, F4
VTYX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-284,250
Change %
-100%
Price
Shares after
0
Date
04 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
284,250
Exercise price
$33.84
Footnotes
F1, F5
VTYX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-466,672
Change %
-100%
Price
Shares after
0
Date
04 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
466,672
Exercise price
$14.48
Footnotes
F1, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Raju Mohan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent.

Footnote F2

At the effective time of the Merger (the "Effective Time"), these shares were automatically converted solely into the right to receive cash in an amount equal to $14.00 (without interest) per share (the "Per Share Price"), subject to the terms and conditions of the Merger Agreement.

Footnote F3

At the Effective Time, each outstanding restricted stock unit ("RSU") that was unvested was cancelled and converted solely into the right to receive a cash award (without interest) equal to (i) the total number of shares of common stock subject to such unvested RSU award immediately prior to the Effective Time, multiplied by (ii) the Per Share Price, less applicable withholding taxes.

Footnote F4

At the Effective Time, this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.

Footnote F5

At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .